Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization

dc.authoridBulut, Hakan/0000-0002-5811-2588
dc.authoridTurgut, Burak/0000-0002-5393-0557
dc.authoridAKPOLAT, Nusret/0000-0002-9138-2117
dc.authorwosidBulut, Hakan/ABA-1433-2020
dc.authorwosidTurgut, Burak/K-8932-2014
dc.authorwosidAKPOLAT, Nusret/ABF-6986-2020
dc.contributor.authorKaya, Mehmet K.
dc.contributor.authorDemir, Tamer
dc.contributor.authorBulut, Hakan
dc.contributor.authorAkpolat, Nusret
dc.contributor.authorTurgut, Burak
dc.date.accessioned2024-08-04T20:40:20Z
dc.date.available2024-08-04T20:40:20Z
dc.date.issued2015
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackgroundThe aim of this study was to compare the effects of lapatinib and trastuzumab on vascular endothelial growth factor on experimental corneal neovascularization. MethodsA total of 35 Wistar albino rats were randomly divided into five groups, each containing seven animals. Corneas of rats in the control group were not cauterized and did not receive any treatment. A silver nitrate pencil was applied on the right corneas of rats in the non-control groups to induce corneal neovascularization. Rats in the sham, lapatinib, trastuzumab and lapatinib+trastuzumab groups were administered systemic saline, 50mg/kg lapatinib once a day orally by gavage, 4mg/kg trastuzumab once a day intraperitoneally, or 50mg/kg lapatinib once a day orally by gavage together with 4mg/kg trastuzumab once a day intraperitoneally, respectively, for 7 days. Rats were sacrificed on the eighth day, and corneas were excised using a 4-mm punch trephine. Vascular endothelial growth factor immunostaining in the corneal epithelial and stromal layers was evaluated. Staining intensities were determined semi-quantitatively, and corneal vascular endothelial growth factor levels were measured by enzyme-linked immunosorbent assay. ResultsThe mean immunostaining intensities of epithelial and stromal vascular endothelial growth factor in the control group were significantly lesser than those in the sham group (P<0.05). The mean immunostaining intensities of epithelial and stromal vascular endothelial growth factor and vascular endothelial growth factor enzyme-linked immunosorbent assay levels of corneas in all treatment groups (lapatinib, trastuzumab and lapatinib+trastuzumab groups) were lesser than those in the sham group (P<0.05); however, it was similar to those in the control group (P>0.05). ConclusionsIt is suggested that systemically administered lapatinib is more effective than systemically administered trastuzumab in preventing corneal neovascularization.en_US
dc.description.sponsorshipFirat University Scientific Research Uniten_US
dc.description.sponsorshipThis work was funded by an unrestricted grant from Firat University Scientific Research Unit (authors' owner institution).en_US
dc.identifier.doi10.1111/ceo.12500
dc.identifier.endpage457en_US
dc.identifier.issn1442-6404
dc.identifier.issn1442-9071
dc.identifier.issue5en_US
dc.identifier.pmid25640924en_US
dc.identifier.scopus2-s2.0-84937024449en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage449en_US
dc.identifier.urihttps://doi.org/10.1111/ceo.12500
dc.identifier.urihttps://hdl.handle.net/11616/96862
dc.identifier.volume43en_US
dc.identifier.wosWOS:000358116200010en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofClinical and Experimental Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcorneal neovascularizationen_US
dc.subjectimmunostainingen_US
dc.subjectlapatiniben_US
dc.subjecttrastuzumaben_US
dc.subjectVEGFen_US
dc.titleEffects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularizationen_US
dc.typeArticleen_US

Dosyalar